Literature DB >> 3356004

Effect of recombinant human interferon-alpha A/D on in vivo murine tumor cell growth.

K Uno1, S Shimizu, K Inaba, M Kitaura, K Nakahira, T Kato, Y Yamaguchi, S Muramatsu.   

Abstract

We investigated the effect of human recombinant interferon-alpha A/D A/D-IFN), which is known to delay the growth of murine tumor cells, on the growth of S1 and R1 subline cells of murine Meth A fibrosarcoma in the peritoneal cavity of mice. In vitro growth of S1 cells was sensitive to, and that of R1 cells was resistant to, the direct effect of A/D-IFN, as with murine natural IFN-alpha/beta, which was used originally to isolate these sublines. In vivo, however, the growth of not only S1 cells but also R1 cells was suppressed by the administration of A/D-IFN, and the survival time of tumor-bearing mice was prolonged. Although A/D-IFN had a direct effect on S1 cells in vivo, R1 cells were susceptible only to the indirect effect via the host cells. Macrophages (M phi) harvested from the peritoneal cavity of A/D-IFN-treated mice bearing ascitic R1 cells were very effective in suppressing the in vitro growth of R1 cells; those from non-R1-bearing A/D-IFN-treated mice were less effective. The results of in vitro experiments indicate that M phi are very probably activated by the synergism of A/D-IFN and M phi diameter-activating factor(s) produced by lymphoid cells in tumor-bearing mice.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3356004

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Impairment of IFN-alpha production capacity in patients with hepatitis C virus and the risk of the development of hepatocellular carcinoma.

Authors:  Kazuko Uno; Yoshiki Suginoshita; Kazuhiro Kakimi; Fuminori Moriyasu; Mayumi Hirosaki; Taro Shirakawa; Tsunataro Kishida
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

2.  Induction of antitumor activity in macrophages by mycoplasmas in concert with interferon.

Authors:  K Uno; M Takema; S Hidaka; R Tanaka; T Konishi; T Kato; S Nakamura; S Muramatsu
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Antitumor effect of combination of murine recombinant interferon beta, murine recombinant interferon gamma and human recombinant interleukin-2 in MethA-bearing mice.

Authors:  T Itoh; Y Sakata; Y Yoshida; K Tsushima; H Suzuki; S Saitoh; Y Tamura; H Ogasawara; N Sugimoto; H Takemori
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Enhanced in vivo sensitivity to interferon with in vitro resistant B16 tumor cells in mice.

Authors:  C M Fleischmann; G J Stanton; W R Fleischmann
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968

5.  In vivo effects of recombinant interferon alpha A/D incorporated in gelatin microspheres on murine tumor cell growth.

Authors:  Y Tabata; K Uno; S Muramatsu; Y Ikada
Journal:  Jpn J Cancer Res       Date:  1989-04

6.  Tumor-specific T cells which form clusters with dendritic cells and tumor cells and deliver macrophage-activating factors.

Authors:  Y Yamaguchi; K Inaba; J Kawai; T Kato; S Nakamura; K Uno; S Muramatsu
Journal:  Jpn J Cancer Res       Date:  1989-02

7.  Potentiation of in vivo antitumor effects of recombinant interleukin-1 alpha by gelatin conjugation.

Authors:  Y Tabata; K Uno; Y Ikada; T Kishida; S Muramatsu
Journal:  Jpn J Cancer Res       Date:  1993-06

8.  Combination therapy of colon carcinoma 26 in mice with recombinant human interleukin-2 and interferon-alpha A/D: occurrence of large granular cells in the tumor.

Authors:  Y Sakura; K Ootsu; A Shino
Journal:  Jpn J Cancer Res       Date:  1989-09

9.  Low-dose interferon-α treatment improves survival and inflammatory responses in a mouse model of fulminant acute respiratory distress syndrome.

Authors:  Daisuke Kudo; Kazuko Uno; Tetsuji Aoyagi; Yukiko Akahori; Keiko Ishii; Emi Kanno; Ryoko Maruyama; Shigeki Kushimoto; Mitsuo Kaku; Kazuyoshi Kawakami
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.